Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BTD??? Help!!!
I´m sure - it is NOT sunrise in that video!
You are correct!
Thay say to have also good results against melanoma and in some years chemo will be (could be) displaced with that therapy....
We will see...... but sounds very good!
So if Heidelberg is part of Sunrise than that patient in that video COULD be in our study! - WOW (if it's true!), because his medicalprozess sounds realy great.
Heidelberg is NOT on the sunrise-list in Germany! Schade! as we say in Austria. So that clinikal study in that video can't be our Sunrise. BUT as it is said in the video: There is HOPE!
CP! Is Heidelberg in Germany part of Sunrise? I can´t find it on:
https://www.clinicaltrials.gov/ct2/show/study/NCT01999673?term=bavituximab&show_locs=Y#locn
http://www.thoraxklinik-heidelberg.de/
http://www.nct-heidelberg.de/
I know they have a clinical lung-cancer study since last summer, but i don´t know if it is sunrise.
I found that Video: "Neue Immuntherapie tötet Krebszellen ab"
New immunotherapy kills cancer cells
http://www.n-tv.de/mediathek/videos/wissen/Neue-Immuntherapie-toetet-Krebszellen-ab-article14428341.html
the list i`v seen today from Black Rock has more then 10k stock-positions (quite a very long list!!!)- PPHM was about #4500(with 10m stocks in pphm/ Sept.2014!!! =14,5M$$$ vol.). List has not been updated so far to see the 12m pphm stocks.
There greatest position is Apple with 225,87m shares (Sept.2014), than Exxon.......
PPHM-ownership as of 30. Sep.2014:
BlackRock: 10,36m shares or 5,69%
now over 12m shares
I´v got the same info from reuters.
Wow - nothing more to say!
come one Bayer....i want to hear something....
I´m waiting there!
OI Call $1,50 01/2015: 4589
Vol up - any News?
Roche to buy majority stake in Foundation for up to $1.18 bln
12-Jan-2015 08:13
• Roche to pay $1.03 bln for outstanding and new shares
• Drugmaker could invest another $150 mln in research funding
• Deal follows purchase of Bina, Dutalys last month
ZURICH/LOS ANGELES Jan 12 (Reuters) - Roche Holding ROG.VX will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc FMI.O for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments.
This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.
Basel-based Roche, which will buy U.S.-based Foundation through a combination of outstanding and newly issued shares, said it is looking for the deal to help to develop combination therapies and more accurately identify cancer patients.
"The intention is to improve decision-making and support optimisation of patient care as oncology management becomes more complex," Roche said in a statement.
The drugmaker said it will tender for about 15.6 million Foundation shares at $50 a share, worth up to about $780 million, at a premium of 109 percent to their Friday closing price. Roche will also invest $250 million in Foundation by acquiring 5 million newly issued shares at $50 per share.
The transactions will result in Roche owning between 52.4 percent and 56.3 percent of Foundation, based in Cambridge, Massachusetts. Roche will obtain minority representation on the board of Foundation, which will retain its current management team.
The initial focus of the collaboration will be on developing genomic profile tests for cancer immunotherapies and for continuous blood-based monitoring. The companies said the deal includes the potential for more than $150 million in additional funding by Roche.
The acquisition comes on the heels of two others. Roche said last month that it would buy privately-held Bina Technologies for an undisclosed price and pay up to $489 million to acquire Austrian biotech company Dutalys. (Full Story)
California-based Bina Technologies provides technology for the processing and management of genomic information, while Dutalys is a specialist in the discovery and development of so-called bi-specific antibodies.
Nice rebound today!
CORRECT - now i´v OI 5427 too!!!!
OI Call 01/2015 $1,50: 2352
Up with no News - thats very good!!!
What i am missing:
Higher volume!
No volume = no news
Dow and NASDAQ red - pphm green
Hmmmm.... time to change the board!
Nice vol.!
OK - one for all others
The roles of phosphatidylserine and
phosphatidylethanolamine in Candida
albicans cell wall maintenance and
mitochondrial function
For my German-reading/speaking friends - i know there are some on this board: ovarian cancer
http://edoc.ub.uni-muenchen.de/16306/1/Gaerth_Julia.pdf
and again PS seems to be (one) problem - page 14!
I talked with some friends these days - they all said to add again in the coming weeks; that would be around 500K pphm - hmmmm.... i hope they do wat they said!
Sounds great
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer PPHM.O - MKW
12-Dec-2014 14:00
For best results when printing this announcement, please click on the link below:
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Statistically Significant Tumor Growth Suppression With Single Agent Bavituximab Equivalent; Statistically Significant Increases in Ratios of Key Indicators of Immune Stimulation With Single Agent Bavituximab Equivalent
TUSTIN, CA--(Marketwired - Dec 12, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13,
2014.
In a poster titled "Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor a-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Breast Tumor Microenvironment," newly published data show that ch1N11, the preclinical equivalent to bavituximab, as a single agent, demonstrated statistically significant (p=0.025) tumor growth inhibition in mice bearing EMT-6 breast tumors when compared to a control antibody. In addition, researchers using fluorescence-activated cell sorting (FACS) found that the single agent treatment of tumor bearing mice with ch1N11 yielded statistically significant increases in the percentage of CD4 (p=0.016) and CD8 (p=0.018) tumor infiltrating lymphocytes and decreases tumor MDSC/CD4 (p=0.026) and MDSC/CD8 (p=0.014) ratios, all key indicators of stimulating immune activation.
"These data supplement previous findings, also discussed in the poster, that the combination of a PS-targeting antibody and an anti-PD-1 antibody demonstrated statistically significant tumor growth inhibition in preclinical breast tumor models compared to anti-PD-1 alone," said Bruce Freimark, Ph.D., director, preclinical research, oncology at Peregrine Pharmaceuticals. "With these results we continue to see positive and consistent data of tumor growth suppression as well as decreases in important immune suppressive activities, making breast cancer a very promising indication for further clinical development."
The link to this poster can be found from the front page of the company's website at: www.peregrineinc.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that data from pre-clinical studies and early stage clinical trials, including ISTs, may not correlate with the results of later stage clinical trials and the risk that data from the company's Immuno-Oncology Development Program and/or translational studies may not correlate to the results of future clinical trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2014 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contact:
Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
© 2014 Marketwire L.P. All rights reserved.
CP sorry for that question: what do you mean with "POISON PILL"?
Vol relative high - mayby it's growing like Summer 2012
1K with $ 1,55 PM